Intensity Therapeutics' INT230-6: Turning Solid Tumors Into Personalized Anti-Cancer Vaccines
Key Insights
Intensity Therapeutics is advancing INT230-6, an intratumoral therapy combining cisplatin and vinblastine with a diffusion enhancer, designed to saturate dense solid tumors (search) while largely avoiding systemic exposure.
The localized approach kills tumor cells directly and triggers a personalized systemic immune response, effectively creating an anti-cancer vaccine from the patient's own tumor that can target both injected and distant metastases.
INT230-6 addresses a key limitation of intravenous immunotherapies by overcoming the "cold" tumor barrier and the Catch-22 of dose-dependent off-target toxicities that damage healthy organs.
Intratumoral cancer therapy has long been hindered by a fundamental physical challenge: many solid tumors (search) — including sarcomas, breast, and pancreatic cancers — are dense, pressurized, and rich in fat, making them impenetrable to traditional water-based drugs. Intensity Therapeutics, a biotech advancing through late-stage clinical development, believes its proprietary chemistry platform has solved this decades-old problem with INT230-6, a novel formulation that combines two potent chemotherapeutic agents with a diffusion and cell-penetration enhancer.
Lew Bender, Founder and CEO of Intensity Therapeutics, outlined the company's approach during the BIO International Convention 2026 in a conversation with BioSpectrum Asia. "We are advancing a novel and precision targeted approach with intratumoral therapy designed to treat solid tumors (search) directly," Bender said. "Historically, tumor injection has been difficult because many tumors are dense, pressurized, and contain a high percentage of fat. Traditional water-based drugs will not disperse or be absorbed effectively in such an environment."
Dual Mechanism: Direct Killing and Immune Activation
INT230-6 is built on a chemistry platform that enables anti-cancer agents to become soluble in both fat and water simultaneously. By combining cisplatin and vinblastine — two potent intravenously administered chemotherapeutics — with a proprietary diffusion enhancer, the formulation achieves broad dispersion throughout the tumor after direct injection, driving the agents into cancer cells while largely avoiding systemic exposure.
The therapeutic strategy extends beyond local tumor destruction. As tumor cells die following injection, they release chemicals personalized to the patient's own cancer. These chemicals are recognized by immune cells capable of training T-cells, effectively educating the immune system to recognize and attack the malignancy. "When we inject a combination of cancer-killing agents directly into a tumor, we are essentially creating a personalized anti-cancer vaccine from the patient's own cancer to fight the cancer," Bender explained. "Once educated, these immune cells enter the bloodstream to seek and destroy cancer cells in the injected tumor and distant, untreated parts of the body with favorable safety."
Bender noted that in preclinical mouse models, the effects of the drug proved protective for the life of the animal.
Overcoming the Immunotherapy Catch-22
Bender highlighted a critical limitation of current systemic immunotherapy approaches: the Catch-22 of dose escalation. Many advanced immunotherapies excel at expanding cytotoxic immune cell populations, yet those cells cannot physically penetrate immunologically "cold" solid tumors (search). To force drug binding to more immune cells, clinicians must increase the dose — but high concentrations of activated immune cells circulating through the body cause off-target toxicities that damage healthy organs without meaningfully attacking the cancer.
"The cancer cells, being from the patient's own tissue, often lack the signals needed to attract immune cells to a meaningful degree, allowing the cancer to grow undetected," Bender said. The agents in INT230-6, cisplatin and vinblastine sulfate, possess dual killing and immune-activating mechanisms of action. With proper dosing into the tumor, these drugs cause the majority of cancer cells to die in an immunologically activating manner, converting a cold tumor into one the immune system can recognize and attack.
Redefining the Treatment Experience
Beyond efficacy, Bender emphasized that reducing treatment-related harm is central to the company's mission. "Current cancer treatments can be harsh for the patients. Sometimes treatment itself can be almost as bad as the cancer, but doctors are left with little choice but to provide their patients the best chance to keep the patient alive," he said. "We want patients to have cancer treatment without the fear of complications from the treatment itself. We want our patients to come out the other side of cancer therapy undamaged."
He added that many cancer patients in remission face permanent health issues from their therapy. INT230-6 aims to change that calculus: "We've created something that will potentially take care of the patients in a way that could both save their lives and not torture them or cause them to have permanent harm."
From Startup to Late-Stage Development
Reflecting on Intensity Therapeutics' journey from startup to late-stage clinical development, Bender offered candid advice for emerging biotech entrepreneurs. "Biotech is not for the faint of heart. You have to believe in your idea and be ready to fight for it," he said. He stressed the importance of communication skills alongside scientific expertise: "Knowing how to pitch investors is as important as the science and your drug development skills. I spend a lot of my time trying to communicate better to investors."
He also noted that acceptance of new technology takes time, and that positive clinical results have made the progress "incredibly rewarding."
Looking Ahead
At BIO 2026, Bender expressed particular excitement about new chemistries making meaningful impacts in cancer care, citing Revolution Medicines' targeted therapy for pancreatic cancer (search) as an example of chemistry-driven success. He positioned INT230-6 as addressing a parallel opportunity: "Our novel chemistry looks to be a solution to the half-century problem of creating a viable intratumoral product that can increase patients' survival, reduce the risk of the disease returning, and allow cancer patients to live better lives after their treatment without unnecessary complications."